CTLA4 and neoplasm: Functioning as a symmetric tetravalent bifunctional antibody, it binds simultaneously with high affinity to PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs), achieving a co-targeting effect that enhances anti-tumor efficacy while enhancing safety [65, 96].